QCG
BDTX icon

Quadrant Capital Group’s Black Diamond Therapeutics BDTX Stock Holding History

Quadrant Capital Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-227
Closed -$988 – 2743
2024
Q3 		$988 Buy
+227
New +$1.24K ﹤0.01% 2597
2021
Q4 		– Sell
-302
Closed -$3K – 2510
2021
Q3 		$3K Buy
+302
New +$2.98K ﹤0.01% 2002

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quadrant Capital Group's BDTX Position: Q4 2024 in Review

Quadrant Capital Group sold out of Black Diamond Therapeutics (BDTX) in Q4 2024, closing a stake of 227 shares — an estimated $988 sold.

Quadrant Capital Group first reported a position in BDTX in Q3 2021 and held it in 2 quarters. The position peaked at $3K in Q3 2021. 87 funds tracked by Wall St. Rank hold BDTX as of Q4 2024.

  • Quadrant Capital Group reported no remaining Black Diamond Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 227 Black Diamond Therapeutics shares in Q4 2024, an estimated $988.
  • Quadrant Capital Group first reported a position in Black Diamond Therapeutics in Q3 2021 and held it in 2 quarters.
  • Quadrant Capital Group's Black Diamond Therapeutics position peaked at $3K in Q3 2021.
  • 87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2024.

Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.